SG11202002743TA - Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations - Google Patents

Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations

Info

Publication number
SG11202002743TA
SG11202002743TA SG11202002743TA SG11202002743TA SG11202002743TA SG 11202002743T A SG11202002743T A SG 11202002743TA SG 11202002743T A SG11202002743T A SG 11202002743TA SG 11202002743T A SG11202002743T A SG 11202002743TA SG 11202002743T A SG11202002743T A SG 11202002743TA
Authority
SG
Singapore
Prior art keywords
frequencies
patient populations
reducing number
convulsive seizures
fenfluramine formulation
Prior art date
Application number
SG11202002743TA
Inventor
Gail FARFEL
Michael Lock
Bradley S Galer
Glenn Morrison
Brooks M Boyd
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Priority claimed from PCT/US2018/052580 external-priority patent/WO2019067413A1/en
Publication of SG11202002743TA publication Critical patent/SG11202002743TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202002743TA 2017-09-26 2018-09-25 Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations SG11202002743TA (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201762563255P 2017-09-26 2017-09-26
US201762564225P 2017-09-27 2017-09-27
US201762579450P 2017-10-31 2017-10-31
US201762593029P 2017-11-30 2017-11-30
US201862627329P 2018-02-07 2018-02-07
US201862669833P 2018-05-10 2018-05-10
US201862696801P 2018-07-11 2018-07-11
US16/139,763 US20190091177A1 (en) 2017-09-26 2018-09-24 Method of treating selected patient population experiencing dravet syndrome
US16/139,704 US20190091176A1 (en) 2017-09-26 2018-09-24 Method of treating selected patient population experiencing dravet syndrome
US16/139,608 US20190125697A1 (en) 2017-09-26 2018-09-24 Method of reduction in convulsive seizure frequency
US16/139,698 US20190091174A1 (en) 2017-09-26 2018-09-24 Method of reducing seizure type experienced by a dravet patient
US16/139,701 US20190091175A1 (en) 2017-09-26 2018-09-24 Method of reduction medication in treating dravet syndrome
US16/139,617 US20190091173A1 (en) 2017-09-26 2018-09-24 Method of increasing time between convulsive seizures
PCT/US2018/052580 WO2019067413A1 (en) 2017-09-26 2018-09-25 Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations

Publications (1)

Publication Number Publication Date
SG11202002743TA true SG11202002743TA (en) 2020-04-29

Family

ID=65806961

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002743TA SG11202002743TA (en) 2017-09-26 2018-09-25 Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations

Country Status (6)

Country Link
US (7) US20190091174A1 (en)
EP (1) EP3687518A1 (en)
JP (1) JP2020535228A (en)
AU (1) AU2018342072B2 (en)
BR (1) BR112020005998A2 (en)
SG (1) SG11202002743TA (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202005916QA (en) 2015-12-22 2020-07-29 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB2597314A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597319A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3035926B1 (en) * 2013-08-19 2020-07-29 The Regents of The University of California Compounds and methods for treating an epileptic disorder
US20170071949A1 (en) * 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy

Also Published As

Publication number Publication date
AU2018342072B2 (en) 2021-05-27
EP3687518A1 (en) 2020-08-05
US20190091173A1 (en) 2019-03-28
JP2020535228A (en) 2020-12-03
US20190125697A1 (en) 2019-05-02
BR112020005998A2 (en) 2020-09-29
US20200276136A1 (en) 2020-09-03
AU2018342072A1 (en) 2020-04-09
US20190091177A1 (en) 2019-03-28
US20190091175A1 (en) 2019-03-28
US20190091174A1 (en) 2019-03-28
US20190091176A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG11202002743TA (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
IL277889A (en) Oligonucleotide compositions and methods of use thereof
IL291933A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
SG11202111387YA (en) Oligonucleotide compositions and methods of use thereof
GB201911281D0 (en) Skincare devices and methods of use
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
HRP20210144T8 (en) Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer
SG11202111386UA (en) Oligonucleotide compositions and methods of use thereof
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
IL247272A0 (en) Quantum-dot spectrometers for use in biomedical devices and methods of use
IL257784A (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
SG11201912185XA (en) Three dimensional tissue compositions and methods of use
ZA201707095B (en) Use of suramin and arginase inhibitors in malignant neoplasia
EP3796920A4 (en) Trna/pre-mirna compositions and use in treating cancer
GB201703115D0 (en) Use of cannabinoids in the treatment of leukaemia
EP3334427A4 (en) Methods of sedation and parenteral formulation for use during critical care treatment
ZA202000502B (en) Cosmetic compositions and methods of use
ZA201706012B (en) Patient incontinence and lifting pad
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
HK1245131A1 (en) Combination comprising palmitoylethanolamide (pea) and lycopene for use in the treatment of inflammatory diseases
EP3261722A4 (en) Compositions comprising pregnancy specific glycoproteins and methods of use thereof
IL312474A (en) Methods and treatment of trauma